In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 8.68 below Celcuity Inc average.

Within Medical Laboratories industry 5 other companies have achieved higher Quick Ratio than Celcuity Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 311, from total ranking in the first quarter 2026 at 686.

Explain Quick Ratio?
How much Cash & cash equivalents CELC�s has?
What are CELC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CELC Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	118.26 %	-25.8 %	741.02 %	47.08 %	103.81 %
Y / Y Cash & cash equivalent Change	347.78 %	88.18 %	87.79 %	72.3 %	-40.51 %
Quick Ratio MRQ	8.68	15.85	8.12	11.76	4.23
CELC's Total Ranking	# 311	# 686	# 451	# 1015	# 785
Seq. Current Liabilities Change	255.64 %	-55.1 %	40.6 %	-2.78 %	20.91 %
Seq. Cash & cash equivalent Change	94.8 %	-12.33 %	-2.96 %	170.2 %	-18.14 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 6
Healthcare Sector	# 190
Overall Market	# 534

Quick Ratio Statistics
High	Average	Low
96.97	22.68	4.23
(Sep 30 2017)		(Jun 30 2025)

Financial Statements
Celcuity Inc 's Current Liabilities	$ 87 Millions	Visit CELC's Balance sheet
Celcuity Inc 's Cash & cash equivalent	$ 754 Millions	Visit CELC's Balance sheet
Source of CELC's Sales		Visit CELC's Sales by Geography

Cumulative Celcuity Inc 's Quick Ratio

CELC's Quick Ratio for the trailling 12 Months

CELC Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	93.75 %	84.61 %	140.31 %	53.65 %	67.63 %
Y / Y Cash & cash equivalent TTM Growth	133.33 %	46.97 %	32.36 %	17.54 %	12.64 %
Quick Ratio TTM	9.97	9.23	7.66	9.03	8.28
Total Ranking TTM	# 553	# 876	# 1038	# 1398	# 1432
Seq. Current Liabilities TTM Growth	29.92 %	-5.12 %	40.66 %	11.74 %	23.79 %
Seq. Cash & cash equivalent TTM Growth	40.33 %	14.28 %	19.39 %	21.86 %	-11.61 %

Quick ratio ranking by company, industry and sector >> Back to CELC Financial Strength Comparisons >> Go to Compare CELC Quick Ratio to its Competitors

On the trailing twelve months basis CELC Cash & cash equivalent more than doubled by 347.78 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Celcuity Inc 's Quick Ratio to 9.97, Quick Ratio remained below CELC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 31 other companies have achieved higher Quick Ratio than Celcuity Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2714.

Explain Quick Ratio?
How much Cash & cash equivalents CELC�s has?
What are CELC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 32
Healthcare Sector	# 857
Within the Market	# 311

trailing twelve months Quick Ratio Statistics
High	Average	Low
38.2	12.51	0.74
(Jun 30 2018)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Medical Laboratories Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Aclarion Inc	15.50	$ 16.285 Millions	$ 1.051 Millions
Miragen Therapeutics Inc	12.67	$ 981.530 Millions	$ 77.484 Millions
Maxcyte inc	10.68	$ 105.690 Millions	$ 9.895 Millions
Grail Inc	10.29	$ 859.755 Millions	$ 83.542 Millions
Absci Corp	10.12	$ 201.142 Millions	$ 19.878 Millions
Billiontoone Inc	9.85	$ 548.628 Millions	$ 55.725 Millions
Celcuity Inc	8.68	$ 754.000 Millions	$ 86.873 Millions
Veracyte Inc	7.76	$ 487.046 Millions	$ 62.736 Millions
Personalis Inc	6.00	$ 278.411 Millions	$ 46.385 Millions
Castle Biosciences Inc	4.72	$ 266.805 Millions	$ 56.509 Millions
Bionexus Gene Lab Corp	4.33	$ 3.522 Millions	$ 0.813 Millions
Caredx Inc	3.99	$ 373.636 Millions	$ 93.698 Millions
Omniab Inc	3.78	$ 51.995 Millions	$ 13.758 Millions
Fulgent Genetics Inc	3.58	$ 257.032 Millions	$ 71.756 Millions
Guardant Health Inc	3.11	$ 1,053.469 Millions	$ 338.962 Millions
Butterfly Network Inc	2.13	$ 124.659 Millions	$ 58.603 Millions
Natera Inc	1.97	$ 1,091.502 Millions	$ 553.200 Millions
Biodesix Inc	1.96	$ 29.996 Millions	$ 15.291 Millions
Sera Prognostics Inc	1.91	$ 46.445 Millions	$ 24.356 Millions
Exagen Inc	1.83	$ 24.588 Millions	$ 13.457 Millions

Date modified: 2026-09-26T07:32:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.